Temperature Treatment of Highly Porous Zirconium-Containing Metal–Organic Frameworks Extends Drug Delivery Release

Citations Over TimeTop 1% of 2017 papers

Abstract

Utilizing metal-organic frameworks (MOFs) as a biological carrier can lower the amount of the active pharmaceutical ingredient (API) required in cancer treatments to provide a more efficacious therapy. In this work, we have developed a temperature treatment process for delaying the release of a model drug compound from the pores of NU-1000 and NU-901, while taking care to utilize these MOFs' large pore volume and size to achieve exceptional model drug loading percentages over 35 wt %. Video-rate super-resolution microscopy reveals movement of MOF particles when located outside of the cell boundary, and their subsequent immobilization when taken up by the cell. Through the use of optical sectioning structured illumination microscopy (SIM), we have captured high-resolution 3D images showing MOF uptake by HeLa cells over a 24 h period. We found that addition of a model drug compound into the MOF and the subsequent temperature treatment process does not affect the rate of MOF uptake by the cell. Endocytosis analysis revealed that MOFs are internalized by active transport and that inhibiting the caveolae-mediated pathway significantly reduced cellular uptake of MOFs. Encapsulation of an anticancer therapeutic, alpha-cyano-4-hydroxycinnamic acid (α-CHC), and subsequent temperature treatment produced loadings of up to 81 wt % and demonstrated efficacy at killing cells beyond the burst release effect.

Related Papers

• CHANGES OF POROSITY VALUE IN ABNORMALLY HIGH PRESSURE GAS RESERVOIRS AND ITS EFFECTS ON THE PRECISION OF RESERVE CALCULATION——A CASE STUDY ON JIA-2 GAS RESERVOIR,MOXI GASFIELD(2007)
• → New Lines in the Spectra of Zirconium(1958)4 cited
• → Determination of Zirconium in Zirconium Metal and Zirconium Powder(1965)1 cited
• a Study of the (triton, Proton) Reaction on Zirconium -90, ZIRCONIUM-92, ZIRCONIUM-94, ZIRCONIUM-96 and TIN-122, TIN-124.(1969)
• → ChemInform Abstract: TETRAKIS(SALICYLALDEHYDATO)ZIRCONIUM(IV) ‐ A USEFUL SYNTHETIC INTERMEDIATE TO ZIRCONIUM SCHIFF BASE COMPLEXES SUCH AS BIS(N,N′‐DISALICYLIDENE‐1,2‐PHENYLENEDIAMINE)ZIRCONIUM(IV)(1978)